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Abstract
Background: We hypothesized that chronic inhibition of epidermal growth factor receptor (EGFR) by cetuximab, a
monoclonal anti-EGFR antibody, induces up-regulation of its ligands resulting in resistance and that microRNAs (miRs) play
an important role in the ligand regulation in head and neck squamous cell carcinoma (HNSCC).
Methodology/Principal Findings: Genome-wide changes in gene and miR expression were determined in cetuximab-
sensitive cell line, SCC1, and its resistant derivative 1Cc8 using DNA microarrays and RT-PCR. The effects of differentially
expressed EGFR ligands and miRs were examined by MTS, colony formation, ELISA, and western blot assays. Heparin-
binding EGF-like growth factor (HB-EGF) and its regulator, miR-212, were differentially expressed with statistical significance
when SCC1 and 1Cc8 were compared for gene and miR expression. Stimulation with HB-EGF induced cetuximab resistance
in sensitive cell lines. Inhibition of HB-EGF and the addition of miR-212 mimic induced cetuximab sensitivity in resistant cell
lines. MicroRNA-212 and HB-EGF expression were inversely correlated in an additional 33 HNSCC and keratinocyte cell lines.
Six tumors and 46 plasma samples from HNSCC patients were examined for HB-EGF levels. HB-EGF plasma levels were lower
in newly diagnosed HNSCC patients when compared to patients with recurrent disease.
Conclusions/Significance: Increased expression of HB-EGF due to down-regulation of miR-212 is a possible mechanism of
cetuximab resistance. The combination of EGFR ligand inhibitors or miR modulators with cetuximab may improve the
clinical outcome of cetuximab therapy in HNSCC.
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Introduction
Epidermal growth factor receptor (EGFR) is a type 1 membrane
tyrosine kinase that plays important roles in differentiation,
proliferation, and metastasis of many human cancers, mostly of
epithelial origin [1]. EGFR represents one of the four members of
the HER family of receptor tyrosine kinases that, upon activation,
engage in complex dimerization patterns depending on the
repertoire of HER family members expressed by individual cell
types. In addition, EGFR has several ligands, including epidermal
growth factor (EGF), transforming growth factor-alpha (TGFA),
heparin-binding EGF-like growth factor (HB-EGF), amphiregulin
(AREG), betacellulin (BTC), epiregulin (EPR) and epigen
(reviewed in [2]). These ligands share a consensus sequence,
known as the EGF motif, which is important for binding to EGFR.
They are frequently produced as transmembrane precursor
proteins that require cleavage by cell surface proteases into soluble
ligands to bind EGFR. TGFA, HB-EGF, AREG and EPR are
cleaved by TNFa-converting enzyme/disintegrin and metallopro-
teinase 17 (TACE/ADAM17), while EGF is cleaved by ADAM10.
PLoS ONE | www.plosone.org 1 September 2010 | Volume 5 | Issue 9 | e12702Once EGFR is activated, it sets off a cascade of downstream
regulator activation including MAPK, AKT and STAT3 (re-
viewed in [1]).
MicroRNAs (miRs) are single-strand RNAs that regulate
mRNA expression [3]. They are transcribed as ,80-nt long
RNA hairpins (primary miRs) and cleaved to ,60-nt precursor
miRs by the protein Drosha in the nucleus [4]. Precursor miRs are
transported to the cytoplasm by Exportin 5, further processed to
,22-nt miRs by the protein Dicer and then loaded into the RNA-
induced silencing complex (RISC) to form mature miRs [5,6].
These mature miRs can inhibit gene transcription by interacting
with promoters, as well as induce mRNA degradation or inhibit
mRNA translation by forming double-strand RNAs [7,8]. The
interactions among the HER family receptors, receptor ligands
and their regulatory miRs are not clearly understood.
Overexpression of EGFR and its ligand, TGFA, is associated
with poor prognosis in HNSCC [9]. In line with these data, such
EGFR-targeted agents as the small molecule tyrosine kinase
inhibitors (i.e. gefitinib and erlotinib) and the monoclonal
antibodies (i.e. cetuximab and panitumumab) provide clinical
benefit to HNSCC patients [10,11,12,13]. Among these agents,
cetuximab is approved by the U.S. Food and Drug Administration
for use in HNSCC patients as a monotherapy, as well as in
combination with radiation or chemotherapy. Recently several
molecular abnormalities were reported to associate with sensitivity
or resistance to EGFR inhibitors, including somatic mutations in
the EGFR tyrosine kinase domain, EGFR gene amplification,
KRAS mutation, and MET amplification [14,15,16,17]. However,
these molecular alterations are extremely rare or not significant for
predicting response to EGFR inhibitors in HNSCC [18,19,20].
Furthermore, most of the patients who are treated with cetuximab
develop resistance over time after an initial response, and
understanding the mechanism of resistance will be paramount to
further optimize the clinical outcome in HNSCC. In this study, we
examined mRNA and miR expression levels in a model system for
cetuximab resistance to determine possible mechanisms of
acquired resistance and to demonstrate that HB-EGF and its
regulator miR212 are involved.
Methods
Cell lines and materials
Cetuximab-resistant cell line, 1Cc8, was derived from cetux-
imab-sensitive SCC1 cells as previously described [21]. The
culture conditions and sources of 34 HNSCC and a spontaneously
immortalized keratinocyte (HaCaT) cell lines used in this study are
described in Table S1. Each cell line was authenticated using a
short tandem repeat analysis kit, Identifiler (Applied Biosystems,
Foster City, CA), as directed at the Johns Hopkins Genetic
Resources Core Facility. Cetuximab (Bristol-Myers Squibb,
Princeton, NJ) was purchased from the Vanderbilt Pharmacy.
Gefitinib was purchased from Tocris Bioscience (Ellisville, MO).
TGFA, HB-EGF and AREG were purchased from R&D Systems
(Minneapolis, MN). TAPI-2 was purchased from Calbiochem (Los
Angeles, CA).
Ethics Statement
Mouse xenograft studies were performed under an Institutional
Animal Care and Use Committee at Office of Animal Welfare
Assurance (IACUC OAWA)-approved protocol. The IACUC
OAWA specifically approved this study (protocol M/07/351).
Frozen tumors and plasma samples from patients with HNSCC
were collected with written informed consents under an Institu-
tional Review Board (IRB) Health Sciences Committee (HSC)-
approved protocol with ‘‘Full Review’’, and the experiments
specific to this study were conducted under an IRB HSC-
approved protocol with ‘‘Expedited Review’’ exempted from
obtaining informed consents for being a minimal-risk study at
Vanderbilt University Medical Center. The IRB HSC specifically
approved this study.
MTS assay and colony formation assay
For MTS assays, cells were seeded in flat-bottom 96-well culture
plates with 1610
3 cells per well in quadruplicate at each dose level
on day zero. The drugs were added on day one as previously
described [21], and the ligands were added every 24 hours. The
culture media and cetuximab were changed on day four and
growth inhibition was measured on day seven. Gefitinib treated
cells were measured on day three. Growth inhibition was
measured using the CellTiter 96 Aqueous One Solution Reagent
(Promega, Madison, WI) according to the manufacturer’s
recommendations. Zero dose-treated cells were measured in four
independent wells for each cell line and data were expressed as a
percentage of growth relative to the zero dose-treated cells. For
colony formation assays, cells were seeded with 2610
4 cells on
Matrigel in flat-bottom 8-well glass plates in triplicate for each
condition on day zero. Quantification of colony number and size
was performed on day five by image analysis. Representative
images were captured by microscope digital camera and analyzed
using NIH supplied Image-J software.
Flow Cytometry
Cells were harvested by trypsinization, washed with phosphate-
buffered saline (PBS), and incubated for 30 minutes on ice with
FITC-labeled cetuximab (5 mg/ml; Pierce Labeling Kit) or with
isotype-matched nonbinding antibody FITC-rituximab (5 mg/ ml)
in PBS containing 0.5% BSA and 2 mM EDTA (FACS buffer).
After washing with PBS, cells were diluted in 0.5 ml of FACS
buffer. Flow cytometry of FITC-labeled cells was performed using
a FACS/Calibur Flow Cytometer (Becton Dickinson, Mansfield,
MA).
Total RNA isolation and analyses
Total RNA was isolated from the cell lines and frozen HNSCC
tumors using Qiagen RNeasy Mini kit according to the
manufacturer’s recommendations (Qiagen, Valencia, CA). Frozen
HNSCC tumors were examined for tumor cellularity and macro-
dissected to enrich for cancer cells to $70% before lysis. The
quality and quantity of the RNA was determined using the Agilent
RNA 6000 NanoLabChip kit and Agilent 2100 bioanalyzer
(Agilent Technologies, Santa Clara, CA). For DNA microarray
analyses, the RNA was labeled with GeneChip
R One-Cycle
Target Labeling and Control Reagents and loaded on to the
Affymetrix Human Genome U133 plus 2.0 GeneChip according
to the manufacturer’s recommendations (Affymetrix, Santa Clara,
CA). The primary microarray data was normalized using Perfect
Match software for further statistical analyses. Normalized
microarray data were imported to GeneSpring 10 (Silicon
Genetics, Redwood City, CA) and analyzed. Genes that were
differentially expressed between cetuximab sensitive and resistant
cell lines were selected using one-way ANOVA with FDR,1%.
For RT-PCR analyses of EGFR ligands in HNSCC tumors,
Applied Biosystems Taqman FAM labeled probes for TGFA, HB-
EGF, NRG1, AREG and EGF were obtained and analyzed
according to the manufacturer’s recommendations (Applied
Biosystems, Foster City, CA). All data are MIAME compliant
and the raw data have been deposited in Gene Expression
Omnibus (GSE21483).
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Total RNAs were isolated from each cell line using Recover All
Total Nucleic Acid Isolation kit according to the manufacturer’s
recommendations (Ambion INC, Austin, TX). The quality and
quantity of the RNA was determined using the Agilent RNA 6000
NanoLabChip kit and Agilent 2100 bioanalyzer (Agilent Tech-
nologies, Santa Clara, CA). Total RNA was used to run the ABI
Megaplex protocol without pre-amplification (Applied Biosystems,
Foster City, CA). A reaction was run using the ABI miRNA
Reverse transcription kit (#4366596) and Megaplex RT Human
Pool A primers (#4399966). The cDNA per sample was then
transferred to a new tube, diluted with water and Taqman
Universal PCR Master Mix without UNG, 2X (#4324018). Each
sample was then loaded onto its own TLDA card. TLDAs were
queued into the ABI7900HT real time PCR machine and run
with the ABI default TLDA protocol. Data were normalized based
on the control on the TLDA card and analyzed.
Immunoblotting
Cells were lysed with RIPA lysis buffer [1 mM NaVO3, 1 mM
DTT, 1 mM PMSF, phosphatase inhibitor cocktail, and protease
inhibitor cocktail mini tablet (Roche, Indianapolis, IN)] and
sonicated. Protein concentration was quantified with a standard
Bradford absorbance assay. Protein from each sample was
fractionated by SDS-PAGE. Proteins were transferred to nitro-
cellulose membrane and incubated with the appropriate primary
antibodies (total and p-EGFR, -HER2, -HER3, -HER4, -FGFR, -
MET, -AKT, -MAPK and –STAT3, Smad2, and b-Actin; Cell
Signaling Technology, Boston, MA) followed by secondary
antibodies. Signal intensity was determined by Imagegauge
version 4.1 (Fujifilm, Japan). Each gel was normalized to b-Actin.
Detection of ligand levels in the conditioned media and
in plasma
Cells (4610
5 cells/ml per well) were seeded in 6-well culture
plates and each condition was tested in triplicate. Sixteen hours
later the culture medium was aspirated, the cells were washed with
PBS and incubated in serum-free media for 24 hours. Fresh
serum-free culture medium containing cetuximab at the specified
concentrations was added to each well and the cells were
incubated for an additional 24 hours. Cells were isolated by
centrifugation and frozen at 280 degree C until assayed. The
plasma samples from patients were processed and stored according
to the standardized institutional protocol until analysis. All ligands
Figure 1. Determination of cetuximab sensitivity. Cetuximab response determination of SCC1 and 1Cc8 HNSCC cell lines by; A) MTS assay, B)
colony formation assay, C) graphical presentation of the colony formation assay, A. U.- Arbitrary Unit, and D) growth inhibition in mouse xenografts.
CTX-cetuximab. Ctrl-control.
doi:10.1371/journal.pone.0012702.g001
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PLoS ONE | www.plosone.org 3 September 2010 | Volume 5 | Issue 9 | e12702Figure 2. Determination of the EGFR ligand expression and receptor kinase activation in SCC1 and 1Cc8 cell lines. A) Western blot
analyses of receptor tyrosine kinases and their downstream proteins with/without HB-EGF stimulation. B) EGFR and pro-HB-EGF protein expression
levels in mouse-xenograft tumors generated from SCC1 and 1Cc8. C) EGFR ligand levels in conditioned media of SCC1 and 1Cc8 with/without
cetuximab treatment determined by ELISA assays. P-values were generated comparing SCC1 versus 1Cc8 for control or cetuximab treatment
HB-EGF and Cetuximab Response
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ELISA Development System (R&D systems, Minneapolis, MN)
according to the manufacturer’s recommendations.
Modulation of HB-EGF and miR-212 expression
Human GIPZ lentiviral shRNAmir (# RHS4430-98481014)
individual clone used to silence HB-EGF expression and a GIPZ
lentiviral negative control vector were purchased from Open
Biosystems (Rockford, IL). Infectious viruses were produced by co-
transfecting the lentiviral vector and packaging constructs into
293FT cells (Invitrogen, Carlsbad, CA) using Lipofectamine 2000
(Invitrogen, Carlsbad, CA). Infectious lentivirus particles were
harvested 48 hours after transfection. 1Cc8 cells were infected
with each virus and then cultured for 5 days. The miRNA mimics/
inhibitor and negative controls were purchased from Dharmacon
(Lafayette, CO) and introduced into cells by Lipofectamine 2000.
Cells were collected after 48 hours post-transfection. Binding of
miR-212 to HB-EGF was determined by co-transfecting 50 nM of
miR-212 mimics (Dharmacon, Lafayette, CO) and 1 mMo f
miRNA 39UTR target expression clone for Human
NM_0019445.1-HB-EGF (GeneCopoeia Inc., Rockville, MD)
into SCC1 and 1Cc8 cells with lipofectamine 2000 (Invitrogen,
Carlsbad, CA) in 6-well plate. Firefly and Renilla luciferase
activities were measured 48 hours after transfection using Luc-Pair
miR Luciferase Assay Kit (GeneCopoeia Inc., Rockville, MD)
according to the manufacturer’s recommendations.
Cetuximab treatment of cell line xenografts in vivo
Athymic nude mice (4 to 6-week-old females) were obtained
from Harlan Laboratories (Indianapolis, IN). A suspension of
4610
6 cells from each cell line in HBSS was injected subcutane-
ously into the right flank of mice. Tumor volumes were measured
in length and width twice a week. Tumor volumes were calculated
using the formula (length x width
2xp)/6. All planted tumors were
grown for 6 to 8 days until average tumor volume reached
30 mm
3 before treatment. Five mice per group were treated with
intraperitoneal injections of 50 mg/kg cetuximab weekly for 4
weeks. All mice were sacrificed 28 days after the first treatment.
Results
Characterization of EGFR inhibitor sensitivity in HNSCC
cell lines
To assess sensitivity to EGFR inhibitors, MTS assays were
performed with SCC1 and 1Cc8 cells after treatment with
cetuximab and gefitinib (Figure 1A). While SCC1 showed high
sensitivity to cetuximab (IC50, 8.0 nM) and gefitinib (IC50,
273 nM), 1Cc8 showed resistance to cetuximab (IC50, .1 mM)
and gefitinib (IC50, .1 mM). As gefitinib is currently not relevant
in the treatment of HNSCC patients, we focused subsequent
studies on cetuximab resistance. We chose 100 nM (15 mg/ml)
dose of cetuximab for additional studies because this is a receptor
saturating concentration optimal to inhibit growth of EGFR-
dependent cancer cells in culture [22] and achieved at steady-state
in the plasma of patients receiving cetuximab [23]. Further, there
was no difference in cell viability or proliferation observed beyond
100 nM in our cell lines (data not shown). Colony formation assays
and in vivo mouse xenograft studies confirmed our initial MTS
assay results (Figure 1B–D).
Increased EGFR ligand expression is associated with
cetuximab resistance
The EGFR expression levels and the ability of cetuximab to
bind EGFR were examined using flow cytometry (Figure S1A).
There was no apparent difference in cetuximab binding to EGFR;
however, 1Cc8 had lower expression of EGFR compared to SCC1
(log fluorescence intensity of 34.8 in 1Cc8 cells versus 94.4 of
SCC1 cells). The EGFR mRNA and protein expression levels in
vitro and in tumor lysates from mouse xenografts were lower in
1Cc8 when compared to SCC1 (Figure S1B and Figure 2A–B). As
previously reported [21], the phospho-AKT was significantly
higher in 1Cc8 when compared to SCC1 and there was increased
activation of HER3.
To further detect differentially expressed genes and pathways
that are associated with increased AKT activation despite
decreased EGFR levels in cetuximab resistant cells, we performed
supervised analyses comparing SCC1 and 1Cc8 (the microarray
data were deposited at Gene Expression Omnibus, GSE21483).
We identified 900 probes with greater than two-fold expression
difference and with t-test p-value of less than 0.01 (Table S2).
Using these probes, Ingenuity Pathway Analysis was performed
examining the EGFR signaling pathway and its related genes.
Among these genes, only HB-EGF and PIK3R3 were up-
regulated in 1Cc8 (Figure S1C). To confirm these data, we
examined soluble protein expression levels of HB-EGF and three
other EGFR ligands, AREG, TGFA and EGF for relative
comparison with HB-EGF in conditioned culture media and cell
lysate before and after treatment with cetuximab. Conditioned
culture media from 1Cc8 demonstrated higher levels of active
soluble HB-EGF and AREG compared to SCC1 (Figure 2C).
TGFA levels were not significantly different between the cell lines
before treatment, but cetuximab treatment resulted in a dramatic
increase in TGFA levels in 1Cc8 compared to SCC1. EGF levels
were extremely low in the two cell lines and did not vary with
cetuximab treatment. In the cell lysates, pro-HB-EGF levels were
significantly higher in 1Cc8 compared to SCC1; however, pro-
TGFA levels did not differ between the two cell lines (Figure 2D).
In mouse xenograft tumors, the pro-HB-EGF level was also higher
in 1Cc8 when compared to SCC1 (Figure 2B). Western blot
analysis of TACE/ADAM17 showed that cetuximab treatment
increased TACE/ADAM17 expression in 1Cc8 cells, but not in
SCC1 cells (Figure 2D). These data suggest that HB-EGF may not
depend on its protease for activation while a rapid increase in
soluble TGFA level is caused by an increased activity of its
protease [24,25].
Increased expression of HB-EGF and receptor kinase
crosstalk
Further evaluation of the stimulatory effects of HB-EGF on
downstream proteins showed that HB-EGF robustly activated
AKT, MAPK and STAT3 (Figure 2A). With recent evidence that
HB-EGF can induce epithelial-to-mesenchymal transition (EMT)
[26], we also examined expression of fibroblast growth factor
receptor (FGFR) and Smad2, a downstream effector of trans-
forming growth factor-beta receptor. Interestingly, phospho-
FGFR and Smad2 levels were higher in 1Cc8 when compared
to SCC1, and HB-EGF stimulated FGFR activation and
decreased expression of Smad2 (Figure 2A).
(* P,0.05, ** P,0.01, ***P,0.001). D) Western blot analyses for pro-HB-EGF, pro-TGFA and TACE/ADAM17 levels with/without cetuximab treatment
in cell lysates from SCC1 and 1Cc8. AREG- amphiregulin, EGF- epidermal growth factor, HB-EGF- heparin-binding EGF-like growth factor, TGFA-
transforming growth factor alpha.
doi:10.1371/journal.pone.0012702.g002
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receptors, the ability to activate each receptor for each ligand was
examined in the presence of cetuximab (Figure 3A). Three ligands,
AREG, HB-EGF and TGFA, activated EGFR even in the
presence of cetuximab in both cell lines, but the effects of EGF on
EGFR in the presence of cetuximab were minimal. The EGFR
activation was the highest after stimulation with HB-EGF, and
only HB-EGF could activate HER-4 with lesser degrees in 1Cc8
when compared to SCC1, consistent with the lower expression of
the receptors in 1Cc8. However, phospho-AKT and –MAPK
levels were higher in 1Cc8 further supporting our finding that
there may be activation of receptors other than EGFR.
HB-EGF knockdown reverses resistance to cetuximab
To establish a causal relationship between increased EGFR
ligand levels and cetuximab resistance, we repeated cell prolifer-
ation assays in the presence of exogenous ligands (AREG, HB-
EGF and TGFA) in the cetuximab sensitive cell line, SCC1
(Figure 3B). Addition of ligand to culture media induced
cetuximab resistance in SCC1. Low concentrations of TGFA
and HB-EGF were sufficient to confer resistance to cetuximab,
whereas addition of AREG at these concentrations was not as
effective. It is possible that TGFA and HB-EGF may have a higher
affinity to the receptor compared to AREG; therefore, TGFA and
HB-EGF may more readily compete for receptor binding in the
setting of prolonged cetuximab exposure. These findings were
confirmed in two additional cetuximab-sensitive HNSCC cell lines
(SCC25, IC50=6.19 nM and SCC15, IC50=6.45 nM, Figure 3B).
The effects of HB-EGF on cetuximab resistance were further
examined by colony formation assays in serum-free media. As seen
in the MTS assay, addition of HB-EGF effectively reversed cell
growth inhibition by cetuximab in SCC1 (Figure 3C).
To further investigate the role of increased TGFA after
cetuximab treatment in cetuximab-resistant 1Cc8 cells, we
examined the effect of TACE/ADAM17 inhibition on cell
growth/viability by treating the cells with TNF protease
inhibitor-2 (TAPI-2), a broad-spectrum inhibitor of MMPs and
TACE/ADAM17 [27]. Results from the MTS assay show TAPI-2
as a monotherapy has a limited effect on SCC1 and 1Cc8 (SCC1,
IC50=30.32 mM, and 1Cc8, IC50.100 mM). In combination with
cetuximab, TAPI-2 enhanced the effect of cetuximab in SCC1,
but cellular growth rates were similar to TAPI-2 monotherapy in
1Cc8 (Figure S2A). Therefore, it appears that increased TGFA
levels after cetuximab treatment do not significantly contribute to
cetuximab resistance seen in 1Cc8. The elevated TGFA level may
simply reflect inhibition of TGFA binding to EGFR by cetuximab
and subsequent decrease in the TGFA/EGFR internalization.
Based on these data, we further investigated the significance of
HB-EGF in cetuximab resistance by using HB-EGF-specific
shRNA to silence its expression. Transfected 1Cc8 cells expressed
lower levels of pro-HB-EGF accompanied by increased sensitivity
to cetuximab (Figure 3D).
HB-EGF is regulated by miR-212 and decreased
expression of miR-212 is associated with cetuximab
resistance
Because regulation of EGFR ligand levels appears to be a
dynamic process, we examined the role of miRs in the ligand
regulation, which is a rapid mechanism of regulating the mRNA
expression levels, and its association with cetuximab sensitivity. We
performed miR expression analyses using RT-PCR-based arrays
examining 384 unique miRs. Among the differentially expressed
miRs, miR-212 showed a 27-fold decrease in 1Cc8 relative to
SCC1 (Table 1). Because a miR can regulate multiple genes, we
obtained a list of 205 genes in Targetscan 5.1 (http://www.
targetscan.org) that are putatively targeted by miR-212, and
examined their gene expression levels in SCC1 and 1Cc8. There
were 32 genes that were differentially expressed between SCC1
and 1Cc8 with p-values of less than 0.05 by t-test (Figure 4A).
Among the 32 genes, HB-EGF was the only gene known to have
Figure 3. Effects of EGFR ligands in cetuximab sensitivity. A) Western blot analyses of HER family receptor kinases and their downstream
proteins with/without EGFR ligand stimulation in the presence of cetuximab. B) Induction of cetuximab resistance by exogenous EGFR ligands in
three cetuximab sensitive HNSCC cell lines determined by MTS assay. C) Induction of cetuximab resistance by exogenous HB-EGF in SCC1 determined
by colony formation assay. D) Pro-HB-EGF level in the cell lysate of 1Cc8 after knockdown of HB-EGF shown in Western blot. Growth inhibition rate of
1Cc8 cells transfected with shRNA HB-EGF and an empty vector measured by MTS assay.
doi:10.1371/journal.pone.0012702.g003
Table 1. Top 20 differentially expressed microRNAs.
SCC1.1Cc8 SCC1,1Cc8
miRNA Fold Change miRNA Fold Change
hsa-miR-212-4373087 27.8 hsa-miR-146a-4373132 41.4
hsa-miR-423-5p-4395451 9.5 hsa-miR-93-4373302 13.0
hsa-miR-483-5p-4395449 7.0 hsa-miR-202-4395474 11.1
hsa-miR-628-5p-4395544 7.0 hsa-miR-597-4380960 7.3
hsa-miR-361-5p-4373035 5.1 hsa-miR-523-4395497 5.7
hsa-miR-95-4373011 5.0 hsa-miR-138-4395395 5.7
hsa-miR-342-3p-4395371 4.5 hsa-miR-135a-4373140 3.6
hsa-miR-219-1-3p-4395206 4.3 hsa-miR-886-3p-4395305 3.6
hsa-miR-491-5p-4381053 4.0 hsa-miR-542-3p-4378101 3.4
hsa-miR-375-4373027 4.0 hsa-miR-193a-5p-4395392 3.0
SCC1: cetuximab-sensitive cell line.
1Cc8: cetuximab -resistant cell line.
doi:10.1371/journal.pone.0012702.t001
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PLoS ONE | www.plosone.org 7 September 2010 | Volume 5 | Issue 9 | e12702Figure 4. Identification of microRNA-212 as a potential regulator of HB-EGF expression. A) Top 20 genes putatively targeted by miR-212.
The numbers next to the gene symbols are p-values. Red: higher gene expression, Green: lower gene expression. B) Relative expression of top 10
miRs targeting HB-EGF in SCC1 and 1Cc8. C) Relative expression levels of miR-212 and HB-EGF in 34 HNSCC cell lines and a keratinocyte cell line. HB-
EGF expression data were obtained from DNA microarray analyses and miR-212 expression data were obtained from TLDA microRNA arrays.
doi:10.1371/journal.pone.0012702.g004
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many miRs, we obtained a list of 10 miRs in Targetscan 5.1
(http://www.targetscan.org) that putatively target HB-EGF and
found that only miR-212 showed a significant difference between
SCC1 and 1Cc8 (Figure 4B). To determine whether this
association could be generalized to other cell lines, we examined
HB-EGF and miR-212 expression levels in an additional 32
HNSCC cell lines and a keratinocyte cell line (Figure 4C). In this
analysis, there was an inverse correlation between HB-EGF and
miR-212 levels (Spearman r=20.37, p=0.036), with the
exception of JHU022. Interestingly, JHU022 was the only cell
line with a heterozygous deletion of the region containing miR-
212 in chromosome 17p13 using available SNP data (Figure S2B).
We further established a negative regulation of miR-212 on HB-
EGF by adding a miR-212 mimic into 1Cc8. The resistant cell
line, 1Cc8, was transfected with a miR-212 mimic, or with a
negative control. After transfection, HB-EGF expression was
dramatically decreased compared to the negative control
(Figure 5A). Using two additional cell lines (JHU12 and TU167)
in which expression of HB-EGF and miR-212 were similar to that
in 1Cc8, we determined that both cell lines showed a clear down-
regulation of HB-EGF expression following transfection with the
miR-212 mimic. Furthermore, a combination of the miR-212
mimic and cetuximab was more effective in growth inhibition in
colony formation assay using 1Cc8 compared to cetuximab or the
miR-212 mimic alone (Figure 5B). Direct binding of miR-212 to
39UTR of HB-EGF was confirmed using a luciferase assay which
showed significant decrease of HB-EGF in the presence of miR212
in 1Cc8 (p=0.038) while the significance was not in SCC1
(p=0.47, Figure 5C). In addition, we examined the effects of miR-
212 antagomir/inhibitor in SCC1 by colony formation assay on
matrigel. Inhibition of miR-212 increased growth as expected, but
the antagomir did not significantly affect the cetuximab sensitivity
in SCC1 (Figure 5D). This suggests that the regulation of HB-EGF
by miR-212 may be specific to a biological context of cetuximab
resistance in 1Cc8, and HB-EGF may be regulated by mecha-
nisms other than miR-212 in cetuximab sensitive SCC1 cells.
HB-EGF expression levels vary significantly in tumors and
plasma from HNSCC patients taken at the time of
diagnosis and of recurrence
To examine whether there is differential expression of EGFR
ligands in human tumors, we determined expression levels of
TGFA, HB-EGF, NRG1, AREG and EGF by RT-PCR in one
normal oral mucosa, two HNSCC tumors taken at the time of
diagnosis, and four HNSCC tumors taken at the time of
Figure 5. MicroRNA-212 regulates HB-EGF expression in cetuximab resistant cells. A) Pro-HB-EGF expression following the transfection
with miR-212 mimics in three cetuximab resistant cell lines. B) Growth inhibition rate of 1Cc8 cells with exogenous miR-212 mimics, cetuximab or a
combination of miR-212 mimics and cetuximab measured by colony formation assay. C) MicroRNA-212 directly regulates HB-EGF by binding to the 39
untranslated region of HB-EGF in cetuximab resistant 1Cc8 cells while it was not significant in cetuximab sensitive SCC1 cells (*, p=0.47; **, p=0.038).
RLU – Raw Light Units. D) Growth rate comparison of SCC1 cells in the presence of cetuximab, exogenous miR-212 inhibitor, or a combination of miR-
212 inhibitor and cetuximab measured by colony formation assay.
doi:10.1371/journal.pone.0012702.g005
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were consistently expressed in all tumors, and the expression levels
of HB-EGF were much higher compared to TGFA and AREG in
HNSCC. As seen in the HNSCC cell lines, the expression levels of
EGF in the tumors were very low. Because the tumors taken at the
time of recurrence suggested having higher expression of HB-EGF
compared to those taken at the time of diagnosis before any
treatment, we examined HB-EGF levels in 16 plasma samples
taken at the time of diagnosis and 30 plasma samples taken at the
time of recurrence (Figure 6B and Table 3). This analysis revealed
that the average plasma HB-EGF level in patients with recurrence
was more than five times higher than in patients with newly
diagnosed tumors: 95 pg/ml versus 23 pg/ml, respectively
(p=0.017, Wilcoxon rank test). It may have a clinical implication
since cetuximab is currently used to treat recurrent disease. Our
results suggest that it may be better employed in upfront therapy
rather than after recurrence with higher levels of HB-EGF.
However, the direct correlation between HB-EGF expression
levels and response to cetuximab could not be ascertained due to
lack of samples from patients uniformly treated with cetuximab in
a sample size with a statistical power.
Discussion
Overexpression of EGFR is associated with poor prognosis in
HNSCC. The EGFR inhibitor cetuximab is the only molecularly
targeted agent to show significant survival benefits in HNSCC
patients as monotherapy or in combination with radiation and/or
chemotherapy [9,12,13]. However, little is known about the
mechanisms of cetuximab resistance in HNSCC. In this paper, we
demonstrate that increased expression of HB-EGF regulated by
miR-212 and activation of receptor kinases other than EGFR by
HB-EGF may play an important role in acquired resistance to
cetuximab.
We observed increased expression of EGFR ligands and
decreased expression of EGFR in cetuximab-resistant cells. In a
Figure 6. The HB-EGF levels in patients with HNSCC. A) Relative expression levels of five ligands in one normal oral mucosa and six tumors
from patients with HNSCC. B) HB-EGF protein levels in plasma from patients with HNSCC. ‘‘Primary’’ plasma samples were taken at the time of
diagnosis. ‘‘Recurrent’’ samples were taken at the time of recurrence.
doi:10.1371/journal.pone.0012702.g006
Table 2. Tumor characteristics from patients with head and neck squamous cell carcinoma.
Patient ID Tumor Type Age at Dx Ethnicity Sex Tumor Site
TNM
Stage at Dx Tumor Diff
182frT2 Primary tumor 59 W M OP T1N3M0 Mod
1756frT2 Primary tumor 45 W M L T4N2cM0 Mod
1352frT3A Recurrent primary tumor 51 W F OC T1N0M0 Mod
1624frT2 Recurrent primary tumor 62 W F OC T2N0M0 Mod
48frT3 Recurrent primary tumor 55 W M HP T2N1M0 Poor
609frT2 Recurrent lymph node 65 W M OP T3N2cM0 Mod
Dx: diagnosis, OP: oropharynx, L: larynx, OC: oral cavity, HP: hypopharynx, Tumor Diff: histological differentiation by pathology, Mod: moderately differentiated, Poor:
poorly differentiated.
doi:10.1371/journal.pone.0012702.t002
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cetuximab resistance, the resistant cells (1Cc8) showed increased
activation of EGFR, HER3, and MET and subsequent activation
of AKT compared to sensitive cells (SCC1) [21]. In the current
study, while we observed increased expression of HER3, MET,
and AKT in 1Cc8 cells, we did not observe increased levels of
EGFR in both in vitro and in vivo studies. This partial difference
may be due to increased activation of EGFR by up-regulation of
ligands causing increased receptor internalization and the lower
detectable level of EGFR in the current study. In addition, the
current study employed serum-starved cells to isolate the impact of
specific EGFR ligand stimulation. In the previous study,
experiments were conducted with 10% fetal bovine serum in the
culture medium, thus up-regulation of EGFR may be the result of
stimulation by other growth factors in the medium.
Epidermal growth factor receptor ligands have been studied in
several cancers as potential biomarkers for EGFR-targeted
therapy; however, the results have been mixed depending on
organ sites and clinical specimens used for testing [16,18]. In a
study by Cohen et al., changes in serum TGFA levels in patients
treated with gefitinib was not associated with their clinical
response to gefitinib [18]. In a study by Mutsaers et al., TGFA
levels were also increased in a dose-dependent manner in the
plasma of EGFR-negative colon cancer patients during cetuximab
treatment [25]; however, increased TGFA levels did not associate
with cetuximab response in a colon cancer clinical trial [28]. These
data are supported by our findings that a TACE/ADAM17
inhibitor did not reverse cetuximab resistance in our model cell
line. However, increased expression levels of AREG and EPR in
tumors of colon cancer patients are associated with cetuximab
sensitivity. In contrast, our results suggest that increased HB-EGF
may be correlated with cetuximab resistance. This discrepancy
could be due to tissue specificity of the EGFR ligand regulation, or
expression of other HER family receptors and downstream
response upon EGFR activation, which is poorly understood in
the context of EGFR inhibitor resistance at this time. In addition,
it could be that the association to cetuximab resistance is due to
characteristics of HB-EGF itself compared to other ligands.
Heparin-binding EGF-like growth factor is known to bind both
EGFR and HER4 and has several unique properties compared to
other EGFR ligands (reviewed in [29,30]). HB-EGF is transcribed
as a transmembrane protein (pro-HB-EGF) and cleaved at the
juxtamembrane domain into soluble HB-EGF (sHB-EGF),
inducing a mitogenic response in keratinocytes [31,32]; however,
unlike other ligands, pro-HB-EGF is alsobiologically active through
juxtacrine signaling to neighboring cells [33]. In our study, both
sHB-EGF and pro-HB-EGF levels were elevated in cetuximab-
resistant cells. In addition, the carboxy-terminal fragment of pro-
HB-EGF (HB-EGF-C) is known to translocate to the nucleus and
bind promyelocytic leukemia zinc finger protein (PLZF), which is a
transcription factor that negatively regulates the cell cycle through
suppressing the expression of cyclin A [34]. Binding of HB-EGF-C
to PLZF causes nuclear export of PLZF and induces cell cycle
progression [34,35]. Knockout mice lacking HB-EGF result in
perinatal or postnatal lethality from defects in heart chamber and
valve formation, abnormal development of lungs, and a significant
defect in epidermal wound healing [36,37] while knockout mice
lacking all three major EGFR ligands (EGF, TGFA and AREG)
resultinmammary glandimpairment and smallintestinedefectsbut
are viable and fertile [38,39]. In line with its role in keratinocyte
migration, there is direct evidence that HB-EGF can induce EMT,
enhance metastasis, and modulate chemotherapy resistance
[26,40,41,42]. Interestingly, one of the proposed resistance
mechanisms that associate with EGFR inhibitors in HNSCC is
EMT [43,44,45]. In our previous work, we showed that an EMT-
linked gene expression profile is associated with a high risk of
recurrence in HNSCC [46]. Our data suggest that HB-EGF may
have a direct role in cetuximab resistance and EMT potentially by
Table 3. Plasma characteristics from patients with head and neck squamous cell carcinoma.
Plasma taken at Dx (n=16) Plasma taken at recurrence (n=30) Total
Age (mean) 59 54 N/A
Sex F 36 9
M 13 23 36
N/A 01 1
Tumor Subsites OC 81 0 1 8
OP 71 1 1 8
HP 01 1
L 06 6
Other 11 2
N/A 01 1
Tumor Stage at Diagnosis 1 04 4
2 12 3
3 35 8
4 12 18 30
N/A 01 1
Tumor differentiation Well 42 6
Moderate 10 15 25
Poor 21 1 1 3
N/A 02 2
doi:10.1371/journal.pone.0012702.t003
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The characteristics of juxtacrine and paracrine signaling and a
mechanism of FGFR activation upon HB-EGF stimulation, as well
as its role in EMT in the context of cetuximab resistance are
currently being investigated.
Lastly, this is the first study to show that a miR has an important
role in regulating a receptor ligand. While the importance of miR
regulation in cancer has been known for several years, the
regulation of receptor ligands by miRs has not previously been
reported. Our data implicate miR-212 as a critical component of
HB-EGF regulation in the setting of cetuximab resistance and that
its level is inversely correlated with HB-EGF levels in various
HNSCC cell lines. In a comprehensive analysis of miRs in
HNSCC cell lines by Tran, et al., miR-212 was reported to be one
of the miRs with low expression [47]. We also found that JHU022,
a cell line with a deletion in the chromosomal region containing
miR-212, had an aberrantly high level of HB-EGF. While the
extent of oncogenic dependency to a single copy loss of miR-212
and subsequently increased HB-EGF in JHU022 requires further
investigation, these data propose a novel mechanism that
abnormal regulation of EGFR ligands by genetic gain or loss of
miR-containing loci may promote carcinogenesis.
In conclusion, our study suggests that one potential mechanism
of acquired resistance to cetuximab involves increased expression
of HB-EGF, and that HB-EGF is regulated by miR-212 and may
have an active role in inducing EMT. Further studies are required
to understand the role of EGFR ligands and their regulation
through miRs, and the induction of EMT as a novel approach to
overcome EGFR inhibitor resistance.
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